Contineum Therapeutics, Inc. $CTNM Shares Bought by UBS Group AG

UBS Group AG boosted its holdings in Contineum Therapeutics, Inc. (NASDAQ:CTNM) by 191.1% in the 4th quarter, HoldingsChannel.com reports. The firm owned 199,389 shares of the company’s stock after buying an additional 130,885 shares during the quarter. UBS Group AG’s holdings in Contineum Therapeutics were worth $2,279,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. acquired a new position in Contineum Therapeutics in the fourth quarter valued at $43,000. Strs Ohio acquired a new position in Contineum Therapeutics in the first quarter valued at $27,000. Bank of America Corp DE increased its stake in Contineum Therapeutics by 500.0% in the third quarter. Bank of America Corp DE now owns 7,236 shares of the company’s stock valued at $85,000 after purchasing an additional 6,030 shares during the last quarter. Qube Research & Technologies Ltd acquired a new position in Contineum Therapeutics in the second quarter valued at $43,000. Finally, Marex Group plc acquired a new position in Contineum Therapeutics in the second quarter valued at $45,000.

Contineum Therapeutics Trading Down 1.9%

CTNM stock opened at $13.44 on Thursday. The stock has a 50-day moving average price of $13.24 and a two-hundred day moving average price of $12.86. Contineum Therapeutics, Inc. has a 12-month low of $3.35 and a 12-month high of $16.33. The company has a market cap of $502.52 million, a PE ratio of -6.89 and a beta of 0.89.

Contineum Therapeutics (NASDAQ:CTNM) last issued its earnings results on Tuesday, May 5th. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.16. Equities analysts forecast that Contineum Therapeutics, Inc. will post -1.79 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently commented on CTNM shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Contineum Therapeutics in a research note on Monday, April 20th. Robert W. Baird upped their target price on Contineum Therapeutics from $14.00 to $20.00 and gave the company an “outperform” rating in a research note on Friday, March 6th. Morgan Stanley upped their target price on Contineum Therapeutics from $14.00 to $16.00 and gave the company an “equal weight” rating in a research note on Thursday, May 14th. Finally, Wall Street Zen upgraded Contineum Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Contineum Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $20.00.

About Contineum Therapeutics

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist.